Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMDUVCZ)

Drug Name
IPH-2101 Drug Info
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMDUVCZ

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
MHC class I NK cell receptor 2DL1 (CD158A) TT4UXPE KI2L1_HUMAN Modulator [2]
MHC class I NK cell receptor 2DL2 (CD158b1) TTU0P73 KI2L2_HUMAN Modulator [2]
MHC class I NK cell receptor 2DL3 (CD158b2) TTEX3SI KI2L3_HUMAN Modulator [2]
MHC class I NK cell receptor 2DS1 (CD158h) TTVWAGF KI2S1_HUMAN Modulator [2]
MHC class I NK cell receptor 2DS2 (CD158j) TTV3CFI KI2S2_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
MHC class I NK cell receptor 2DL2 (CD158b1) DTT KIR2DL2 4.413 3.797 3.963 3.787
MHC class I NK cell receptor 2DL3 (CD158b2) DTT KIR2DL3 4.248 5.433 4.868 4.263
MHC class I NK cell receptor 2DL1 (CD158A) DTT KIR2DL1 4 2.263 2.485 2.766
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Bone marrow
The Studied Disease Multiple myeloma [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
MHC class I NK cell receptor 2DL2 (CD158b1) DTT KIR2DL2 1.69E-05 -0.93 -3.58
MHC class I NK cell receptor 2DL3 (CD158b2) DTT KIR2DL3 5.34E-04 -0.32 -2.19
MHC class I NK cell receptor 2DL1 (CD158A) DTT KIR2DL1 2.29E-06 -0.43 -4.42
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01222286) Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma. U.S. National Institutes of Health.
2 Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.